Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17669941 | 1.00 | LDHA (0.50) | LDHACYP2C9TSHRSLC6A4CYP1A2 | |
| SCHEMBL1262676 | 0.82 | LDHA (0.53) | LDHACYP2C9TSHRSLC6A4CYP1A2 | |
| SCHEMBL17680419 | 0.82 | PPARA (0.39) | PPARAPPARGPPARDIDO1 | |
| SCHEMBL2578194 | 0.82 | PPARA (0.39) | PPARAPPARGPPARDIDO1 | |
| SCHEMBL7254097 | 0.82 | ESR1 (0.46) | PPARA | |
| SCHEMBL2557410 | 0.81 | SLC6A2 (0.44) | SLC6A4PPARAPPARG | |
| SCHEMBL6204861 | 0.80 | TRPA1 (0.50) | CYP2C9SLC6A4CYP1A2CYP2C19PPARA | |
| SCHEMBL28548708 | 0.80 | KMT2A (0.44) | LDHACYP2C9TSHRSLC6A4CYP1A2 | |
| SCHEMBL6813922 | 0.79 | PPARA (0.53) | PPARAPPARGPPARD | |
| SCHEMBL17683698 | 0.78 | CASR (0.48) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550719-B2 | Process for the preparation of 3-aryl-2-hydroxy propanoic acid compounds | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-01-24 | — | — | US | disclosed |
| US-20160102042-A1 | A PROCESS FOR THE PREPARATION OF 3-ARYL-2-HYDROXY PROPANOIC ACID COMPOUNDS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-04-14 | — | — | US | disclosed |
| US-7132092-B2 | Metallized mesoporous silicate and method of oxidation with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20050090688-A1 | Metallized mesoporous silicate and method of oxidation with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1473275-A1 | METALLIZED MESOPOROUS SILICATE AND METHOD OF OXIDATION WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102042-A1 | A PROCESS FOR THE PREPARATION OF 3-ARYL-2-HYDROXY PROPANOIC ACID COMPOUNDS | P4HA1, HCAR1, HPD | LDHA 273/4885CYP2C9 207/4885TSHR 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.